All In Biotech

Drug Trial Radar · NCT00099359

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission

Last checked: Nov 19, 2026Latest source record: Dec 4, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,735 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,735

Actual

Start

Feb 2004

Primary completion

Feb 2011

Study completion Feb 2011

Sponsor

Sponsor type
NIH
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Dec 13, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, up to 2 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Giving anti-HIV medications to babies born of HIV positive mothers right after birth can lower the babies' risk of contracting HIV. This study will assess the safety and efficacy of two different combinations of anti-HIV medications compared to a one drug standard regimen in preventing mother to baby transmission. The one drug standard treatment and two combinations to be studied are: 1) zidovudine, 2) zidovudine/nevirapine and 3) zidovudine/lamivudine/nelfinavir.

Conditions

  • Disease Transmission, Vertical
  • Vertical Human Immunodeficiency Virus Transmission
  • HIV Infections

Interventions

  • ZidovudineDrug

    Given for 6 weeks. 12mg PO BID if birthweight (BW) \> 2000 grams 8 mg PO BID if BW \< 2000 grams

  • Nevirapine (NVP)Drug

    Standard of Care (Zidovudine) plus NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose : 12 mg PO per dose if BW \> 2000 grams, 8 mg PO per dose if BW \< 2000 grams

  • Epivir (3TC)Drug

    Stand of care (Zidovudine) plus 3TC, given for 2 weeks: 6 mg po bid if BW \> 2000 grams 4 mg po bid if BW \< 2000 grams AND NFV, given for 2 weeks: 200 mg po bid if BW \> 3000 grams 150 mg po bid if BW \> 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams

  • Nelfinavir (NFV)Drug

    200 mg BID if birth weight (BW) \> 3000 grams for 2 weeks;150 mg BID if BW \> 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Infant HIV Infection StatusTime frame: 3 months
  2. Participants With Serious Adverse EventsTime frame: through age 6 months.

Locations

17 sites in 5 countries. Site status is shown where the registry gives one.

  • Miller Children's Hospital

    Long Beach, California

  • University of FL

    Gainesville, Florida

  • University of FL-HSC

    Jacksonville, Florida

  • University Medical and Dental School of NJ-Newark Campus

    Newark, New Jersey

  • Texas Childrens Hospital

    Houston, Texas

  • Hospital I. G. A. Dr. Diego Paroissien

    Buenos Aires, Argentina

  • Hospital dos Servidores do Estado (HSE)

    Rio de Janeiro, Brazil

  • Hospital Geral de Novo Iguacu

    Rio de Janeiro, Brazil

  • 5088 - Universidade Federal de Sao Paulo (UFSP)

    São Paulo, Brazil

  • Federal University of Minas Gerais (UFMG)

    Belo Horizonte, Minas Gerais, Brazil

  • Universidade de Sao Paulo (USP) , MD

    São Paulo, Ribeirão Preto, Brazil

  • Hospital Fêmina S.A. Unidade Perinatal de Transmissão Vertical

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Santa Casa (HSC)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao (GHC)

    Porto Alegre, Rio Grande do Sul, Brazil

  • San Juan Hospital

    San Juan, Puerto Rico

  • Tygerberg Hospital

    Cape Town, South Africa

  • Chris Hani Baragwanath Hospital

    Johannesburg, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.